OSE Immunotherapeutics (XPAR:OSE) FFO


XPAR:OSE OSE Immunotherapeutics SA XPAR:OSE
53 GF Score
Price €3.15
GF Value €1.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:OSE
53GF Score
OSE Immunotherapeutics SA XPAR:OSE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OSE Immunotherapeutics (XPAR:OSE) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.15 is trading 111.1% above its estimated GF Value™ of €1.49. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:OSE:

  • FFO:
  • GF Value™: €1.49 vs. price of €3.15 (111.1% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the XPAR:OSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OSE Immunotherapeutics Business Description

Other Exchanges ORPOF:USA0RAD:UK6OP:Germany
Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
53GF Score

Get the complete analysis for XPAR:OSE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.15
Price
€1.49
GF Value